I-Mab Net Assets
I-Mab net assets. Based on the latest financial reports, I-Mab (IMAB) has net assets worth $258.92 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($277.41 Million) and total liabilities ($18.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMAB net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $258.92 Million |
| % of Total Assets | 93.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | -96.43% |
| 10-Year Change | N/A |
| Growth Volatility | 25.93 |
Net Assets of I-Mab (2017–2024)
Net assets of I-Mab from 2017 to 2024. This chart illustrates how I-Mab's net assets have evolved over time, based on quarterly financial data. See I-Mab (IMAB) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for I-Mab (2017–2024)
The table below shows the annual net assets of I-Mab from 2017 to 2024. For live market cap and overall valuation, see market cap of I-Mab.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $201.16 Million | -88.29% |
| 2023-12-31 | $1.72 Billion | -42.89% |
| 2022-12-31 | $3.01 Billion | -34.43% |
| 2021-12-31 | $4.59 Billion | -18.47% |
| 2020-12-31 | $5.63 Billion | +376.56% |
| 2019-12-31 | $-2.03 Billion | -113.03% |
| 2018-12-31 | $-955.10 Million | -218.59% |
| 2017-12-31 | $-299.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to I-Mab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 92817900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
I-Mab Net Assets Breakdown (December 2024)
I-Mab net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.01% |
| Other Comprehensive Income | $33.38 Million | 16.60% |
| Other Components | $1.45 Billion | 722.71% |
| Total Equity | $201.16 Million | 100.00% |
I-Mab Competitors by Market Cap
The table below lists competitors of I-Mab ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CHC Resources Corp
TW:9930
|
$456.51 Million |
|
Zhejiang Tiantai Xianghe Industrial Co Ltd
SHG:603500
|
$456.77 Million |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
$456.79 Million |
|
Sinopec Shandong Taishan Petroleum Co Ltd
SHE:000554
|
$456.92 Million |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
$456.44 Million |
|
Anshan Senyuan Road Bridge
SHE:300210
|
$456.32 Million |
|
Bradespar S.A
SA:BRAP3
|
$456.23 Million |
|
GENERAL Elevator Co. Ltd.
SHE:300931
|
$456.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in I-Mab's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,718,156,000 to 201,160,000, a change of -1,516,996,000 (-88.3%).
- Net loss of 162,257,000 reduced equity.
- Share repurchases of 335,000 reduced equity.
- Other comprehensive income decreased equity by 6,387,000.
- Other factors decreased equity by 1,348,017,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-162.26 Million | -80.66% |
| Share Repurchases | $335.00K | -0.17% |
| Other Comprehensive Income | $-6.39 Million | -3.18% |
| Other Changes | $-1.35 Billion | -670.12% |
| Total Change | $- | -88.29% |
Book Value vs Market Value Analysis
This analysis compares I-Mab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-5.15 | $3.96 | x |
| 2018-12-31 | $-16.42 | $3.96 | x |
| 2019-12-31 | $-34.98 | $3.96 | x |
| 2020-12-31 | $82.31 | $3.96 | x |
| 2021-12-31 | $60.40 | $3.96 | x |
| 2022-12-31 | $36.46 | $3.96 | x |
| 2023-12-31 | $20.64 | $3.96 | x |
| 2024-12-31 | $2.48 | $3.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently I-Mab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-80.66%) is below the historical average (-36.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -2580.82% | 0.01x | 0.00x | $-268.26 Million |
| 2018 | 0.00% | -749.02% | 0.02x | 0.00x | $-307.32 Million |
| 2019 | 0.00% | -4950.00% | 0.02x | 0.00x | $-1.28 Billion |
| 2020 | 8.37% | 30.53% | 0.24x | 1.13x | $-91.80 Million |
| 2021 | -50.82% | -2648.70% | 0.02x | 1.23x | $-2.79 Billion |
| 2022 | -83.35% | 0.00% | 0.00x | 1.35x | $-2.81 Billion |
| 2023 | -85.31% | -32674.02% | 0.00x | 1.52x | $-1.64 Billion |
| 2024 | -80.66% | 0.00% | 0.00x | 1.06x | $-182.37 Million |
Industry Comparison
This section compares I-Mab's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| I-Mab (IMAB) | $258.92 Million | 0.00% | 0.07x | $456.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more